These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19926405)

  • 21. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection.
    Grebely J; Pham ST; Matthews GV; Petoumenos K; Bull RA; Yeung B; Rawlinson W; Kaldor J; Lloyd A; Hellard M; Dore GJ; White PA;
    Hepatology; 2012 Apr; 55(4):1058-69. PubMed ID: 22031335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C virus infection among a cohort of Victorian injecting drug users.
    Crofts N; Hopper JL; Bowden DS; Breschkin AM; Milner R; Locarnini SA
    Med J Aust; 1993 Aug; 159(4):237-41. PubMed ID: 7692222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
    Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
    Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.
    Tsui JI; Evans JL; Lum PJ; Hahn JA; Page K
    JAMA Intern Med; 2014 Dec; 174(12):1974-81. PubMed ID: 25347412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of hepatitis C virus (HCV) RNA load in platelets of HCV-monoinfected patients receiving antiviral therapy.
    Espírito-Santo MP; Brandão-Mello CE; Marques VA; Lampe E; Almeida AJ
    Ann Hepatol; 2013; 12(3):373-9. PubMed ID: 23619253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy.
    Hallinan R; Byrne A; Amin J; Dore GJ
    J Gastroenterol Hepatol; 2005 Jul; 20(7):1082-6. PubMed ID: 15955218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance.
    Mauss S; Berger F; Goelz J; Jacob B; Schmutz G
    Hepatology; 2004 Jul; 40(1):120-4. PubMed ID: 15239094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.
    Grebely J; Hellard M; Applegate T; Petoumenos K; Yeung B; Feld JJ; Rawlinson W; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews GV;
    AIDS; 2012 Aug; 26(13):1653-61. PubMed ID: 22555168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection.
    Alvarez-Uria G; Day JN; Nasir AJ; Russell SK; Vilar FJ
    Liver Int; 2009 Aug; 29(7):1051-5. PubMed ID: 19580634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
    Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL
    Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department.
    Hutton J; Doyle J; Zordan R; Weiland T; Cocco A; Howell J; Iser S; Snell J; Fry S; New K; Sloane R; Jarman M; Phan D; Tran S; Pedrana A; Williams B; Johnson J; Glasgow S; Thompson A
    Int J Drug Policy; 2019 Oct; 72():84-90. PubMed ID: 31351752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
    Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
    World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up.
    Dalgard O; Bjøro K; Hellum K; Myrvang B; Skaug K; Gutigard B; Bell H;
    Eur Addict Res; 2002 Jan; 8(1):45-9. PubMed ID: 11818693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin.
    Waizmann M; Ackermann G
    J Subst Abuse Treat; 2010 Jun; 38(4):338-45. PubMed ID: 20362408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.
    Doyle JS; Deterding K; Grebely J; Wedemeyer H; Sacks-Davis R; Spelman T; Matthews G; Rice TM; Morris MD; McGovern BH; Kim AY; Bruneau J; Lloyd AR; Page K; Manns MP; Hellard ME; Dore GJ;
    J Viral Hepat; 2015 Dec; 22(12):1020-32. PubMed ID: 26098993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic.
    Kieran J; Dillon A; Farrell G; Jackson A; Norris S; Mulcahy F; Bergin C
    Int J STD AIDS; 2011 Oct; 22(10):571-6. PubMed ID: 21998177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
    Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
    AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project.
    Lindenburg CE; Lambers FA; Urbanus AT; Schinkel J; Jansen PL; Krol A; Casteelen G; van Santen G; van den Berg CH; Coutinho RA; Prins M; Weegink CJ
    Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):23-31. PubMed ID: 21042221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addicts with chronic hepatitis C: difficult to reach, manage or treat?
    Zanini B; Benini F; Pigozzi MG; Furba P; Giacò E; Cinquegrana A; Fasoli M; Lanzini A
    World J Gastroenterol; 2013 Nov; 19(44):8011-9. PubMed ID: 24307794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.